Kicking off 2026: Sparked by the long-awaited rise of non-opioid treatments, the first-ever - will capitalize on Vertex's recent success to transform efficacy and tolerability of pain management with Nav 1.8 & beyond: With rising anticipation for new targets like tau and LRRK2, the & returns as your flagship end-to-end forum for building on anti-amyloid approvals and strengthening biomarker assessments to reinvigorate the neurodegenerative treatment landscape: Concentrating on earlier-stage innovation, will unite those dedicated to translating discoveries of glial biology and peripheral immune pathways into novel approaches to target neuroinflammation across the neurodegenerative disease spectrum: Full details of the 2026 event schedule can be found in your copy of the World CNS 2026 Prospectus below
The statements on this website have not been evaluated by the Food and Drug Administration (FDA)
Biochemistry 32 , 705710 (1993)
Additionally, it may regulate oxidative stress and platelet activation in surgical process [36]
This immune-focused blend delivers IV fluids, vitamin C, zinc, and B vitamins
The Bottom Line The traditional PBM model forces an impossible choice on GLP-1s
